Ai2, a Manchester, UK-based biotechnology company, received a £100,000 Grant for Research and Development (GRAND), the incentive aimed at helping entrepreneurs and business owners introduce innovative products and processes, including research trials and product testing.
The funding will be used to research a new use for their peptide-based product for contact lenses, using it in a hydrogel for wound dressings.
Ai2, which employs 8 people, develops innovative technology to prevent infection on a wide range of commonly used medical devices. It was founded in 2005 as a spin out from Manchester University to commercialise the discoveries made by Ai2 founder and CEO, Curtis Dobson.
GRAND is part of Solutions for Business, the UK Government’s package of publicly funded business support designed to help companies start and grow. It is funded by the European Regional Development Fund (ERDF) with £1.1m as well as the Northwest Regional Development Agency (NWDA) with £1.2m.